Relay Therapeutics (RLAY): Chief Legal Officer sold ~$6.1K

~$6.1K

Approx. value · 1,637 sh @ $3.74

390K

Holds after · shares reported

Traded

Jul 28, 2025

Filed

Jul 30, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jul 9, 2025Insider · 1 personInsiders: 2 sales (~$219K)
2. Jul 28, 2025 · this disclosureInsiderOfficer sold ~$6.1K of RLAY shares in the open market

What came next

1. Jul 28, 2025Insider · 3 peopleInsiders: 3 sales (~$27K)
2. Jul 29, 2025Insider · 4 peopleInsiders: 4 sales (~$291K)
3. Nov 4, 2025Company filing · Form 8-K · Results, Executive changeChanged a top executive or board member, and reported its results (and 1 more item)“On November 4, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors (the "Board") of the Company increased the number of members of the Board from seven to nine and appointed each of Lonnel Coats and Habib Dable as members of the Board, effective as of November 4, 2025.”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Relay Therapeutics

For Relay Therapeutics, OQRO holds 8 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its RLAY page.

Other recent filings by Brian Adams, Chief Legal Officer

• SEC Form 4 at Relay Therapeutics (RLAY)Jul 30, 2025
• SEC Form 4 at Relay Therapeutics (RLAY)May 1, 2025
• SEC Form 4 at Relay Therapeutics (RLAY)May 1, 2025
• SEC Form 4 at Relay Therapeutics (RLAY)Mar 31, 2025
• SEC Form 4 at Relay Therapeutics (RLAY)Jan 31, 2025

The full history of Brian Adams, Chief Legal Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Relay Therapeutics

• SEC Form 4Oct 30, 2026
• SEC Form 4Oct 30, 2026
• SEC Form 4Oct 30, 2026
• SEC Form 4Oct 8, 2026
• SEC Form 4Oct 8, 2026
• SEC Form 4Oct 8, 2026

Everything OQRO holds on this company is on its RLAY page.